Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB11 | A5LHX3 | 6/20 | 0.49 |
| ▸ | PSMA7 | O14818 | 6/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 6/20 | 0.49 |
| ▸ | PSMA1 | P25786 | 6/20 | 0.49 |
| ▸ | PSMA2 | P25787 | 6/20 | 0.49 |
| ▸ | PSMA3 | P25788 | 6/20 | 0.49 |
| ▸ | PSMA4 | P25789 | 6/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 6/20 | 0.49 |
| ▸ | PSMB9 | P28065 | 6/20 | 0.49 |
| ▸ | PSMA5 | P28066 | 6/20 | 0.49 |
| ▸ | PSMB4 | P28070 | 6/20 | 0.49 |
| ▸ | PSMB6 | P28072 | 6/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.49 |
| ▸ | PSMB10 | P40306 | 6/20 | 0.49 |
| ▸ | PSMB3 | P49720 | 6/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.49 |
| ▸ | PSMA6 | P60900 | 6/20 | 0.49 |
| ▸ | PSMA8 | Q8TAA3 | 6/20 | 0.49 |
| ▸ | PSMB7 | Q99436 | 6/20 | 0.49 |
| ▸ | CTSD | P07339 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5969992 | 1.00 | PSMB11 (0.49) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL5969989 | 0.83 | ATM (0.48) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL5970246 | 0.81 | KMT2A (0.47) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL5970043 | 0.81 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL5970055 | 0.81 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL5970218 | 0.80 | PSMB5 (0.48) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL5970212 | 0.80 | PSMB5 (0.48) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL5970152 | 0.80 | PSMB11 (0.70) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL5970165 | 0.80 | PSMB11 (0.70) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL5970013 | 0.79 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205673-A1 | 2-Amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives | FURET PASCAL | 2006-09-14 | — | — | US | disclosed |
| EP-1290012-B1 | 2-AMINO-3-HYDROXY-4-TERT-LEUCYL-AMINO-5-PHENYL-PENTANOIC ACID AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| US-20030166572-A1 | 2-Amino-3-hydroxy-4-tert-leucyl-amino-5 phenyl-pentanoic acid amide derivatives | FURET PASCAL (FR) | 2003-09-04 | — | — | US | disclosed |
| EP-1290012-A2 | 2-AMINO-3-HYDROXY-4-TERT-LEUCYL-AMINO-5-PHENYL-PENTANOIC ACID AMIDE DERIVATIVES | Novartis AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001089282-A2 | 2-AMINO-3-HYDROXY-4-TERT-LEUCYL-AMINO-5-PHENYL-PENTANOIC ACID AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166572-A1 | 2-Amino-3-hydroxy-4-tert-leucyl-amino-5 phenyl-pentanoic acid amide derivatives | AADAT, ABAT, TTR | PSMB11 3049/4885PSMA7 1382/4885PSMB1 3071/4885 |
| US-20060205673-A1 | 2-Amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives | AADAT, ABAT, ALB | PSMB11 3104/4885PSMA7 1544/4885PSMB1 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.